Nestlé's forward revenue growth turns positive 1.0% by H2 2024
Nestlé's 17.95x P/E expands to 21x by Q1 2025
Nestlé's EPS growth justifies 17.95x P/E by H1 2025
Recent Daily Analysis
— Nestlé’s deceptive stability, outperforming a weak sector by staying flat, masks a significant, unpriced vulnerability to pharmacological disruption. We hypothesize that the market is treating Nestlé as a safely diversified staple while completely ignoring the direct revenue threat from the widespread adoption of GLP-1 weight-loss drugs. These drugs directly target the consumption patterns that fuel Nestlé's high-margin confectionery, frozen foods, and ice cream categories. The current 17.9x P/E reflects a pre-GLP-1 consumer world, making the stock a potential value trap as this secular shift in consumption habits accelerates and permanently impairs its core profit centers.